John Carbona
John Carbona is the former CEO of AveXis, a biotech startup that developed Zolgensma, the groundbreaking gene therapy for spinal muscular atrophy (SMA). His leadership and management played a critical role in transitioning the therapy from research to commercialization, significantly impacting drug pricing discussions.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
John Carbona was the CEO of AveXis, the biotech startup that developed Zolgensma.
5